What is claimed is:

1. Use of an antibody, or antigen binding fragment thereof, that specifically binds to a B cell maturation antigen (BCMA), in the manufacture of a medicament for treating multiple myeloma (MM)in a subject in need, wherein one or more doses are to be independently administered to the subject at about 100 mg of the antibody or antigen-binding fragment to about 2,000 mg of the antibody or antigen-binding fragment.

2. The use of claim 1, wherein the antibody or antigen-binding fragment thereof is a non-fucosylated antibody or antigen-binding fragment, or

wherein a composition comprising the antibody or antigen-binding fragment thereof is to be administered to the subject, about or at least 95%, 97%, 98% or 99% of the antibody or antigen-binding fragment thereof in the composition are afucosylated.

3. The use of claim 1 or 2, wherein the antibody or antigen binding-fragment thereof, comprises:

(a) a heavy chain variable region comprising a CDR1 comprising SEQ ID NO: 1, a CDR2 comprising SEQ ID NO: 2, and a CDR3 comprising SEQ ID NO: 3, and

a light chain variable domain comprising a CDR1 comprising SEQ ID NO: 5, a CDR2 comprising SEQ ID NO: 6, and a CDR3 comprising SEQ ID NO: 7;

or

(b) wherein the antibody or the antigen-binding fragment thereof comprises a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO: 4 and a light chain variable domain comprising an amino acid sequence of SEQ ID NO: 8.

4. The use of any one of claims 1-3, wherein the antibody or the antigen-binding fragment is humanized, or wherein the antibody is an IgG1 antibody.

5. The use of any one of claims 1-4, wherein the one or more doses are to be independently administered to the subject at about 800 mg of the antibody or antigen-binding fragment to about 2,000 mg of the antibody or antigen-binding fragment; or

wherein the one or more doses are to be independently administered to the subject at about 1,200 mg of the antibody or antigen-binding fragment to about 2,000 mg of the antibody or antigen-binding fragment; or

wherein the one or more doses are to be independently administered to the subject at about 1,400 mg of the antibody or antigen-binding fragment to about 1,800 mg of the antibody or antigen-binding fragment; or

wherein the one or more doses are to be independently administered to the subject at about 400 mg of the antibody or antigen-binding fragment; or

wherein the one or more doses are to be independently administered to the subject at about 800 mg of the antibody or antigen-binding fragment; or

wherein the one or more doses are to be administered to the subject at about 1,600 mg of the antibody or antigen-binding fragment.

6. The use of any one of claims 1-5, wherein two or more doses of the antibody or antigen-binding fragment are to be administered to the subject, optionally

wherein the two or more doses are to be administered to the subject at a frequency of between once a week and about once every four weeks; or

wherein the two or more doses are to be administered to the subject at a frequency of about once a week; or

wherein the two or more doses are to be administered to the subject at a frequency of about once every two weeks; or

wherein the two or more doses are to be administered to the subject at a frequency of about once every three weeks; or

wherein the two or more doses are to be administered to the subject at a frequency of about once every four weeks.

7. The use of claim 6, wherein each dose comprises 800 mg of the antibody or antigen-binding fragment and is to be administered to the subject every 2 weeks; or

wherein each dose comprises 1600 mg of the antibody or antigen-binding fragment and is to be administered to the subject every 2 weeks.

8. The use of claim 6, wherein individual doses of the antibody or antigen-binding fragment are to be administered to the subject on day 1 and day 15 of a 28-day cycle; or

wherein the doses of the antibody or antigen-binding fragment are to be administered to the subject for multiple 28-day cycles.

9. The use of any one of claims 1-8, wherein the one or more doses comprise one or more induction doses that are to be administered to the subject during an induction phase and one or more maintenance doses that are to be administered to the subject during a maintenance phase after the one or more induction doses have been administered.

10. The use of claim 9, wherein one of the induction doses is to be administered to the subject about once a week for about 1-10 weeks; or

wherein one of the induction doses is to be administered to the subject once a week for 8 weeks; or

wherein one of the induction doses is to be administered 4 times within a 28-day cycle; or

wherein one of the induction doses is to be administered 8 times within two 28-day cycles; or

wherein one of the induction doses is to be independently administered on day 1, day 8, day 15 and day 22 for each of two 28-day cycles.

11. The use of any one of claim 9 or 10, wherein the one or more maintenance doses are to be administered once every 1-4 weeks after completion of the induction phase; or

wherein one of the maintenance doses is to be administered once every two weeks; or

wherein one of the maintenance doses is to be administered on day 1 and day 15 of a 28-day cycle.

12. The use of claim 9, wherein the antibody or antigen-binding fragment is dosed q1wk during the induction phase for a total of 8 induction phase doses and dosed q2wk during the maintenance phase.

13. The use of claim 9, wherein:

each induction dose comprises 100, 200, 400, or 1600 mg of the antibody or antigen-binding fragment;

each maintenance dose comprises 100, 200, 400, or 1600 mg of the antibody or antigen-binding fragment;

one of the induction doses is to be administered on each of day 1, day 8, day 15 and day 22 for each of two 28-day cycles for a total of 8 induction doses during the induction phase; and

one of the maintenance doses is to be administered on each of days 1 and day 15 of each of one or more subsequent cycles.

14. The use of claim 9, wherein each induction dose and each maintenance dose comprises 800 or 1600 mg of the antibody or antigen-binding fragment; or

wherein each induction dose and each maintenance dose comprises 1600 mg of the antibody or antigen-binding fragment.

15. The use of any one of claims 1-14, wherein one or more doses of dexamethasone is further to be administered to the subject.

16. The use of claim 15, wherein the one or more doses of dexamethasone are to be independently administered to the subject at a frequency of once a week; or

wherein one of the doses of the antibody or antigen-binding fragment are to be administered at a frequency of about once every 1-4 weeks and the doses of dexamethasone are to be administered at a frequency of about once every 1-4 weeks; or

wherein one of the doses of the antibody or antigen binding fragment are to be administered once every two weeks and one of the doses of dexamethasone is to be administered once every two weeks; or

wherein one of the doses of the antibody or antigen binding fragment is to be administered once every two weeks and one of the doses of dexamethasone is to be administered once every week; or

wherein one of the doses of the antibody or antigen binding fragment is to be administered on each of day 1 and day 15 of a 28-day cycle and one of the doses of dexamethasone is to be administered on each of day 1, day 8, day 15 and day 22 of the same 28-day cycle.

17. The use of claim 9, wherein:

one of the doses of the antibody or antigen-binding fragment is to be administered once a week during an induction phase with subsequent doses following the induction phase being administered once every two weeks during a maintenance phase; and

one of the doses of dexamethasone is to be administered once every week; and optionally:

(a) wherein:

one of the doses of the antibody or antigen-binding fragment is to be administered once a week for 8 weeks during the induction phase and subsequent doses are to be administered once every two weeks during the maintenance phase; and

one of the doses of dexamethasone is to be administered once every week; or

(b) wherein:

one of the doses of the antibody or antigen-binding fragment is to be administered on each of day 1, day 8, day 15, and day 22 of each of two 28-day cycles and then on each of day 1 and day 15 of subsequent 28-day cycles; and

one of the doses of dexamethasone is to be administered on each of day 1, day 8, day 15, and day 22 of each of the 28-day cycles.

18. The use of any one of claims 15-17, wherein each dose of dexamethasone is to be administered as a 20-60 mg dose; or

wherein each dose of dexamethasone is to be administered as a 40 mg dose; or

wherein each dose of dexamethasone is to be administered as a 20 mg dose.

19. The use of any one of claims 1-18, wherein one or more doses of an anti-CD38 antibody, or antigen-binding fragment thereof is further to be administered to the subject, optionally wherein the anti-CD38 antibody is daratumumab.

20. The use of claim 19, wherein the one or more doses of the anti-CD38 antibody or antigen-binding fragment thereof are to be independently administered to the subject at about 5 mg/kg (milligram per kilogram of the body weight) to about 30 mg/kg; or

wherein the one or more doses of the anti-CD38 antibody or antigen-binding fragment thereof are to be independently administered to the subject at about 10 mg/kg to about 20 mg/kg; or

wherein the one or more doses of the anti-CD38 antibody or antigen-binding fragment thereof are to be independently administered to the subject at about 16 mg/kg.

21. The use of claim 19 or 20, wherein two or more doses of the anti-CD38 antibody or antigen-binding fragment are to be administered to the subject, optionally

(a) wherein the two or more doses of the anti-CD38 antibody or antigen-binding fragment thereof are to be administered to the subject at a frequency of about once a week to about once every four weeks; or

(b) wherein the two or more doses of the anti-CD38 antibody or antigen-binding fragment thereof are to be administered to the subject at a frequency of about once a week; or

(c) wherein the two or more doses of the anti-CD38 antibody or antigen-binding fragment thereof are to be administered to the subject at a frequency of about once every two weeks or once every three weeks; or

(d) wherein the two or more doses of the anti-CD38 antibody or antigen-binding fragment thereof are to be administered to the subject at a frequency of about once every four weeks; or

(e) wherein the anti-CD38 antibody or antigen-binding fragment thereof are to be administered to the subject on day 1, day 8, day 15 and day 22 for 28-day cycles.

22. The use of claim 21, wherein two or more doses of the anti-CD38 antibody or antigen-binding fragment thereof are to be administered to the subject at a frequency of about

once every week during a first phase; two or more doses of the anti-CD38 antibody or antigen-binding fragment thereof are to be administered to the subject at a frequency of about once every two weeks to about once every three weeks during a second phase; and two or more doses of the anti-CD38 antibody or antigen-binding fragment thereof are to be administered to the subject at a frequency of about once every four weeks during a third phase.

23. The use of any one of claims 1-22, wherein one or more doses of an immunomodulatory drug is further to be administered, optionally

wherein the immunomodulatory drug is an immunomodulatory imide drug (IMiD), or

wherein the immunomodulatory drug is lenalidomide or pomalidomide.

24. The use of claim 23, wherein the one or more doses of the immunomodulatory drug are to be independently administered to the subject at a frequency of about once per day to about once per week; or

wherein the one or more doses of the immunomodulatory drug are to be independently administered to the subject once per day; or

wherein the one or more doses of the immunomodulatory drug are to be independently administered to the subject once per day on Days 1-21 of repeated 28-day cycles.

25. The use of claim 23 or 24, wherein each dose of the immunomodulatory drug is about 1 mg to about 10 mg; or

wherein each dose of the immunomodulatory drug is about 2 mg to about 4 mg; or

wherein each dose of the immunomodulatory drug is about 4 mg.

26. The use of any one of claims 23-25, (a) wherein the antibody or antigen-binding fragment that specifically binds to BCMA is to be administered to the subject on day 1 and day 15 of a 28-day cycle, dexamethasone is to be administered to the subject on day 1, 8, 15, and 22 of the 28-day cycle, and pomalidomide is to be administered to the subject on days 1-21 of the 28-day cycle; or

(b) wherein one of the induction doses of the antibody or antigen-binding fragment that specifically binds to BCMA is to be administered on each of day 1, day 8, day 15 and day 22 for

two 28-day cycles for a total of 8 induction doses during the induction phase; and one of the maintenance doses of the antibody or antigen-binding fragment that specifically binds to BCMA is to be administered on each of days 1 and day 15 of each of one or more subsequent 28-day cycles in the maintenance phase;

wherein dexamethasone is to be administered to the subject on each of day 1, 8, 15, and 22 of each 28-day cycle in the induction phase and the maintenance phase; and

wherein pomalidomide is to be administered to the subject on days 1-21 of each 28-day cycle in the induction phase and the maintenance phase.

27. The use of any one of claims 1-26, wherein one or more doses of a gamma-secretase inhibitor is further to be administered to the subject, optionally

wherein the gamma-secretase inhibitor is Semagacestat (LY450139), RO4929097, MK-0752, Avagacestat (BMS-708163), BMS-986115, Nirogacestat (PF-03084014), Crenigacestat (LY3039478), BMS-906024, DAPT (GSI-IX), Dibenzazepine (YO-01027), LY411575, L-685,458, NGP 555, MDL-28170, or Itanapraced (CHF 5074).

28. The use of any one of claims 1-27, wherein the subject has previously been diagnosed as having multiple myeloma; or

wherein the subject has been diagnosed as having relapsed or refractory multiple myeloma; or

wherein the subject was previously administered one or more therapeutic agents or treatments for multiple myeloma; or

wherein the subject has previously been administered at least one of a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, or cannot tolerate the foregoing; or

wherein the subject has previously been administered therapeutic agents include all three of a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, or cannot tolerate the foregoing.

29. A kit comprising:

(a) one or more doses of a pharmaceutical composition comprising (i) an antibody, or antigen binding fragment thereof, that specifically binds to a B cell maturation antigen (BCMA), and (ii) a pharmaceutically acceptable carrier, wherein the antibody or antigen binding fragment thereof, comprises: a heavy chain variable region comprising a CDR1 comprising SEQ ID NO: 1, a CDR2 comprising SEQ ID NO: 2, and a CDR3 comprising SEQ ID NO: 3, and a light chain variable domain comprising a CDR1 comprising SEQ ID NO: 5, a CDR2 comprising SEQ ID NO: 6, and a CDR3 comprising SEQ ID NO: 7; and optionally

(b) instructions for performing a use of any one of claims 1-28.

30. The kit of claim 29, wherein the kit further comprises one or more doses of dexamethasone, one or more doses of an immunomodulatory imide drug, one or more doses of a gamma-secretase inhibitor, and/or one or more doses of an anti-CD38 antibody or antigen-binding fragment thereof.